Publication | Closed Access

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Neoadjuvant TherapyNeck 1Randomised Phase 3MedicineHead And Neck CancerCancer TreatmentNeck OncologyOncologyRadiation OncologyCancer ResearchAfatinib Versus MethotrexateRadiologyHealth Sciences